![]() | ![]() |
Formats:
|
||||||||||||||||||||||
Bluetongue virus: dissection of the polymerase complex Polly Roy, Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London WC1E 7HT, United Kingdom; Author contact details: Prof. Polly Roy, Professor of Virology, Department of Infectious & Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, United Kingdom, Tel: 020 7927 2324, Fax: 020 7927 2839, Email: polly.roy/at/lshtm.ac.uk The publisher's final edited version of this article is available free at J Gen Virol.Summary Bluetongue is a vector-borne viral disease of ruminants that is endemic in tropical and subtropical countries. Since 1998 the virus has also appeared in Europe. Partly due to the seriousness of the disease bluetongue virus (BTV), a member of genus Orbivirus within the family Reoviridae, has been a subject of intense molecular study for the last three decades and is now one of the best understood viruses at the molecular and structural levels. BTV is a complex non-enveloped virus with seven structural proteins arranged in two capsids and a genome of ten double-stranded (ds) RNA segments. Shortly after cell entry the outer capsid is lost to release an inner capsid (the core) which synthesises capped mRNAs from each genomic segment, extruding them into the cytoplasm. This requires the efficient co-ordination of a number of enzymes including helicase, polymerase and RNA capping activities. This review will focus on our current understanding of these catalytic proteins as derived from the use of recombinant proteins, combined with functional assays and the in vitro reconstitution of the transcription/replication complex. In some cases, 3D structures have complemented this analysis to reveal the fine structural detail of these proteins. The combined activities of the core enzymes produce infectious transcripts necessary and sufficient to initiate BTV infection. Such infectious transcripts can now be synthesised wholly in vitro and, when introduced into cells by transfection, lead to the recovery of infectious virus. Future studies thus hold the possibility of analysing the consequence of mutation in a replicating virus system. Background The year 2007 was a landmark for Bluetongue disease in the UK with the first outbreak recorded in East Anglia in September followed by Essex, Cambridgeshire and Kent and, by the end of the year, a number of additional cases in various parts of the country (DEFRA, 2008). For both farmers and the public, the outlook for 2008 is necessarily cautious as this is a newly emerging disease in key livestock, sheep and cattle that had not previously been considered a threat. Bluetongue virus (BTV), which is the causative agent of the disease, has been known for >100 years. Its inexorable spread from its origins in South Africa has led to European colonisation over the last 10 years such that its occurrence in the UK was but a matter a time (EFSA, 2007). BTV causes haemorrhagic disease in ruminants and, as such, represents a major economic threat in many parts of the world. It can infect both wild ruminants and domestic livestock, causing disease in sheep, goats, and cattle with mortality reaching 70% in some breeds of sheep. BTV is endemic in many tropical and sub-tropical countries. The virus is transmitted by several species of biting midges (gnats) in the genus Culicoides (Fig. 1
BTV is the type species of the genus Orbivirus within the family Reoviridae. which includes a total of twelve distinct genera (Mertens et al., 2005). Many of these viruses are pathogenic to animals and some also infect or are pathogenic for humans (Orthoreovirus, Rotavirus, Coltivirus and Seadornavirus) (Mertens et al., 2005). Orbiviruses (14 related serogroups, some 140 members) infect animals, plants and insects and are transmitted by arthropods, such as mosquitoes, gnats and ticks. Many of these viruses cause diseases in animals or plants, often with high economic impacts in agriculture and animal health. Although BTV and the related epizootic haemorrhagic disease virus (EHDV) of deer, African horse sickness virus (AHSV), and equine encephalosis virus (EEV) are all transmitted by gnats (Culicoides) and can cause high morbidity and mortality in animals, BTV is the more common throughout the world, often causing serious periodic outbreaks (Erasmus, 1985). As a result of its economic significance, BTV has been the subject of extensive molecular, genetic and structural studies and now represents the best characterised of all the Orbiviruses (Roy, 2007). Viruses of the Reoviridae, including BTV and other orbiviruses, are characterized primarily by their genome of 10–12 segments of linear, double-stranded RNA (dsRNA). Almost all of these separate segments represent single genes, generating a total of 10–13 viral proteins. The virions are non-lipid-containing icosahedral capsid structures, usually with an outer capsid layer surrounding an inner capsid or core that contains the genome. Shortly after cell entry this outer capsid is removed to release the inner capsid within which the genome remains sequestered from the cellular triggers of innate immunity. Cores must necessarily, therefore, carry all the transcription machinery of the virus, synthesising and extruding multiple capped positive (+ve) sense RNAs from each genomic segment into the host cell cytoplasm. Current models for the transcription of the dsRNA genome are based on the polymerase complex contacting the template RNA and the nascent transcript being directed out of the core particle through a pore on its surface. This requires the efficient co-ordination of some half-a-dozen enzyme activities including helicase, polymerase and RNA capping activity. Considerable advances have been made in recent years in understanding the replicase complexes of these viruses, including BTV. Each of the BTV proteins that form the complex has been expressed as a recombinant protein, purified and used to develop an in vitro assay system for activity. This, in turn, has lead to the detailed mapping of the structure-function relationships among each core component. In some cases, three-dimensional structural studies have complemented these analyses to reveal the fine level of structural detail associated with proteins of the BTV inner capsid, their function alone and in combination. This review will be centred on the molecular dissection of these proteins and will discuss recent data that demonstrate how the combined activities of the core enzymes result in the release of infectious transcripts that are necessary and sufficient to establish viral infection. Overview of BTV replication Like the other members of the Reoviridae, BTV virions are non-enveloped, architecturally complex structures composed of multiple layers of proteins. In the case of BTV, there are seven structural proteins (VP1-VP7) organised into an outer capsid and an inner capsid (commonly known as a “core”) containing the ten dsRNA segments of the viral genome. Although the basic features of BTV replication cycle are similar to those of other members of the family, such as reoviruses and rotaviruses, BTV and other orbiviruses multiply in arthropods as well as in vertebrate hosts (Fig. 1 In mammalian cells, BTV entry proceeds via virus attachment to a receptor on the plasma membrane (Eaton & Hyatt, 1989). Through a combination of biochemical and confocal microscopy studies, together with specific inhibitors and RNA interference, it has recently been shown that BTV enters cells by clathrin-mediated endocytosis and pH-dependent penetration (Forzan et al., 2007). The outer capsid proteins of BTV, which are non-glycosylated, are responsible for virus entry and penetration and their structural organisations must facilitate these processes. Image processing of virion micrographs obtained from cryo-electron microscopy (cryo-EM) show a well-ordered morphology with an unique icosahedral organisation (Hewat et al., 1992a; 1994; Nason et al., 2004). The icosahedral virion particle has a diameter of ~88 nm and the outer layer is composed of 180 VP2 molecules and 360 VP5 molecules. The 180 VP2 molecules form 60 spike-like, sail-shaped structures while the 360 VP5 molecules are arranged in 120 globular structures and are located more internally than the VP2 spikes. The VP2 spikes extend 3nm beyond the main body of the particle and are responsible for virus attachment to the cell surface and receptor-mediated endocytosis of the virion (Eaton & Hyatt, 1989; Forzan et al., 2007). BTV entry into the cytoplasm requires endosomal acidic pH which allows the globular VP5 protein to permeablise the endosomal membrane via its amino terminal ‘pore- forming’ peptide, analogous to the fusion peptides of envelope viruses (Hassan et al., 2001; Forzan et al., 2004; Forzan et al., 2007). The membrane penetration activity of VP5 was dramatically shown when VP5 was presented appropriately on the cell-surface and induced cell-cell fusion, confirming that it has the capability to destabilize cellular membranes (Forzan et al., 2004). Critically, VP5 only exhibits its membrane-destabilising properties after it has undergone a low pH-triggered activation step, which presumably mimics the endosomal environment encountered during cell entry and possibly triggers a change in the conformation of the protein (Forzan et al., 2007). VP5 lacks the autocatalytic cleavage and N-terminal myristoyl group present in the entry proteins of reoviruses and rotaviruses and does not require proteolytic activation in contrast to some other viral fusion proteins (Espejo et al., 1981; Estes et al., 1981; Smee et al., 1981; Nibert et al., 1991; Colman & Lawrence, 2003). In the case of rotavirus, the penetration of virus into the cells’ cytoplasm (and probably also the uncoating of the virus particle) is dependent upon trypsin activation of viral outer capsid protein VP4. It is noteworthy that the structural organisation of the outer capsid proteins of rotavirus and reovirus are very different from that of BTV (Nason et al., 2004; Zhang et al., 2005; see review by Pesavento et al., 2006), although in all three groups of viruses the outer capsid proteins perform essentially same function, i.e., entry, membrane penetration and release of transcriptionally active inner capsid into the cytoplasm. Thus, for BTV the current model posits that VP2 makes initial contact with the host cell and triggers receptor mediated endocytosis of the virus particle and then VP5 undergoes a low pH-triggered conformational change that results in the destabilisation of the endosomal membrane (Forzan et al., 2007). It is likely that the change in conformation of VP5 that promotes membrane destabilisation, forming a protein layer with intrinsic outside-in curvature, weakens the contacts between VP5 and the underlying outer layer of the core (Forzan et al., 2004; Forzan et al., 2007). This allows core particles, from which both outer capsid proteins have been lost, to be released into the cytoplasm and initiate genome replication (Van Dijk & Huismans, 1982; Huismans et al., 1987). In addition to being transcriptionally active, cores generated in vitro by proteolytic treatment of purified BTV also retain infectivity for the insect vector and vector-derived cells, indicating that core proteins can also mediate cell attachment and penetration (Mertens et al., 1987). The core is a multi-enzyme complex composed of two major proteins (VP7 and VP3) and three enzymatically active minor proteins (VP1, VP4 and VP6) in addition to the ten segments of dsRNA genome (~19,000 base pairs in total) (Verwoerd et al., 1970; Verwoerd et al., 1972; Fukusho et al., 1989 and see reviews by Roy et al., 1990a; Roy, 1995). Core enzymes transcribe the ten viral genome segments, as well as cap and methylate full-length mRNA copies of each segment (Van Dijk & Huismans, 1982). The mRNAs are not polyadenylated. In the current model of replication, the mRNA molecules synthesised by the parental cores represent the only transfer of genetic information to the next generation of progeny particles. Transcription occurs inside the viral core and involves the extrusion of ‘capped’ and methylated mRNA species that are subsequently translated into viral proteins in the cytoplasm of an infected cell. The genomic dsRNA segments are never released from the core. Biochemical and EM evidence suggests that all ten genome segments are transcribed simultaneously, similar to the reovirus (Gillies et al., 1971; Huismans & Verwoerd, 1973; Bartlett et al., 1974), although the ten mRNA species are not synthesised at the same rate for BTV (Verwoerd & Huismans, 1972). Newly produced viral proteins later interact with sequestered viral mRNA species within cytoplasmic viral inclusion bodies (VIBs) to form proviral particles. These proviral particles are believed to be the sites of dsRNA synthesis and the further production of mRNA prior to eventual formation of complete virus particles and extrusion/release from an infected cell (Lecatsas, 1968; Eaton et al., 1990). The VIBs, predominantly consist of the viral coded non-structural protein, NS2, which is synthesized abundantly in the virus-infected cells and is responsible for recruiting both the core proteins and newly synthesised transcripts (Thomas et al., 1990; Kar & Roy, 2003; Lymperopoulos et al., 2003; Modrof et al., 2005; Lymperopoulos et al., 2006). Although the exact mechanism of genome encapsidation is still not clear, current data suggests that VIBs are the genome encapsidation and assembly sites of the cores. However, outer capsid proteins are not recruited by NS2 and the assembly of outer capsid on the core does not take place within the VIBs. The two outer capsid proteins are processed independently of each other and outside of the VIBs (Bhattacharya et al., 2007; Kar et al., 2007). The smallest of the NS proteins (NS3), which is encoded by the smallest RNA segment (S10), is the only glycosylated protein encoded by BTV and is found associated with both VP2 and VP5 (French et al., 1989; Wu et al., 1992; Beaton et al., 2002). Current data suggests that NS3 is involved both in virus maturation and release (Hyatt et al., 1993; Beaton et al., 2002; Wirblich et al., 2006). Unlike NS2 and NS3, much less is known of the role of the largest NS protein, NS1, which is encoded by RNA segment 6 and synthesises large numbers of tubular structures in the infected cells (Huismans & Els, 1979; Urakawa & Roy, 1988). This is a unique feature of BTV and other orbiviruses and neither rotavirus nor reovirus infected cells exhibit such tubular structures. Current data suggest that NS1 is an essential protein and is involved in virus replication and morphogenesis (Owens & Roy, 2004). The assembly, roles of the outer capsid and NS proteins in the virus life cycle will not be discussed further in this review as these have recently been reviewed elsewhere (Roy, 2005; Noad & Roy, 2006). However, the functions assigned to each of the ten proteins are summarised in Table 1.
The architecture of BTV core particles that facilitate the synthesis and release of viral transcripts BTV cores are highly robust structures and can be generated in vitro from purified virus particles by protease treatment (Van Dijk & Huismans, 1980; 1988). This has facilitated three-dimensional structural analyses which have revealed that the icosahedral surface of the core (73 nm in diameter) has a triangulation number of 13 in a left-handed configuration (T=13l) and is solely made up of 260 trimers of VP7 that are attached onto an inner, thin protein shell (59 nm in diameter) (Prasad et al., 1992; Grimes et al., 1997; Grimes et al., 1998). The core possesses channels at both the icosahedral three-fold and the five-fold axes (Fig. 2
Within the central space of the core crystals, an extra density in layers was visualised and these layers were arranged in a multi-strand helical structure (Grimes et al., 1998; Gouet et al., 1999). The estimated volume of this density was consistent with the molecular mass (~13.1×106 Da) of the BTV genome (19,219 base pairs; (Fukusho et al., 1989), thus implying that these helical layers are the genomic dsRNA segments. The packaging order of these layers appears to be imposed by grooves that form tracks for the RNA on the inside of the VP3 layer but without any specific interactions (Grimes et al., 1998; Gouet et al., 1999). Such an organisation would facilitate the movement of RNA within the core during the transcription activity. Dissecting the enzymatic function(s) of the core proteins The fact that the genome of BTV, like other members of the family, remains within the core and only the single-stranded RNA (ssRNA) transcripts are released indicates that replication of the dsRNA genome does not occur via a semiconservative mechanism analogous to that of dsDNA replication. The ssRNA transcripts that are released from the core must also serve as the template on which dsRNA is formed. The conservative mode of replication of dsRNA was demonstrated as early as 1970 for reovirus (Bannerjee & Shatkin, 1970; Silverstein et al., 1970) and was subsequently confirmed by others in the field. The structural integrity of the core particle appears to be essential for maintaining an efficient transcriptional activity which, in turn, requires the efficient co-ordination of a series of enzyme activities. The BTV core possesses only 3 minor proteins (VP1, VP4, and VP6) which are responsible for synthesising the ‘capped’ and methylated transcripts of each dsRNA segment that are released from the transcribing core into the cytoplasm. In addition to polymerase and capping enzymes, a BTV helicase may also be required to unwind the dsRNA genome prior to the initiation and during the synthesis of mRNA species (Fig. 3
VP6 as a RNA helicase protein Helicase proteins are responsible for unwinding duplex nucleic acids, DNA, RNA and DNA-RNA hybrids. Two essential features are shared by all helicases; ATP hydrolysis, which releases the energy required for helix destabilization and nucleic acid binding site(s) in order to maintain contact with the nucleic acid that is to be unwound (Lohman et al., 1998). Sequence comparisons of a large number of helicases from different organisms have identified these common functional motifs, including putative sequences for RNA binding, ATP binding/hydrolysis and helicase function (Schmid & Linder, 1992; Kadare & Haenni, 1997; de la Cruz et al., 1999; Dillingham & Kowalczykowski, 2001; Tai et al., 2001). RNA helicases also have a particular signature sequence, the DEAD-box or “DECH-box”, which is responsible for forming the protein-ATP complex in the presence of Mg+2 (de la Cruz et al., 1999; Dillingham & Kowalczykowski, 2001). The smallest BTV core protein, VP6 (35.7 kDa), has a high proportion of hydrophilic and positively charged residues and binds both single-stranded and double-stranded RNA (Roy et al., 1990b). Moreover, in the presence of ATP and magnesium ions, the purified soluble VP6 can bind either blunt-ended RNA duplexes or those with short 5′ or 3′ overhangs and unwind the duplex efficiently in vitro (Fig. 4
Although the exact mechanism of helicase action is still unclear, a number of models have been proposed in which the helicase protein could be active as a monomer, dimer or hexamer (Ahnert & Patel, 1997; Bird et al., 1998; Lohman et al., 1998). The soluble VP6 is a monomer but very rapidly forms stable hexamers, particularly in the presence of ssRNA and dsRNA (Fig. 4 The largest protein VP1 is the RNA-dependent RNA polymerase The RNA-dependent RNA polymerase (RdRp) is an essential protein encoded by all RNA viruses that replicates their genome via an RNA intermediate. For BTV, the first indication that the largest BTV protein, VP1 (Mr of 149.5 kDa) is the virus polymerase protein came from sequence comparison with other DNA and RNA polymerases and from a poly(A) polymerase assay system that used a crude extract of insect cells infected with a recombinant baculovirus expressing only BTV VP1 (Fukusho et al., 1989; Urakawa et al., 1989). Subsequent studies have used a purified recombinant protein for an in vitro polymerase assay. These data showed that the soluble BTV VP1 is an active enzyme which exhibits a processive replicase activity in the absence of any other viral proteins and initiates BTV minus-strand synthesis de novo (Boyce et al., 2004). The in vitro reaction conditions for VP1 replicase activity used in these experiments were equivalent to that of the optimal transcriptase activity of intact BTV core particles which indicated that there is no major change in polymerase activity caused by dissociation of VP1 from the rest of the core complex (Van Dijk & Huismans, 1980; Mertens et al., 1984; Van Dijk & Huismans, 1988). These data contrast with those of rotavirus and reovirus. In rotavirus it has been suggested that the assigned polymerase protein (VP1) alone is incapable of performing the polymerase activity in an in vitro assay system, being only functional when it was attached to the inner shell (Chen et al., 1994; Patton et al., 1997; Tortorici et al., 2003). Similarly, it was reported that the assigned polymerase protein of reovirus was incapable of synthesising de novo RNA on its own, although it was shown that a short RNA oligonucleotide could be generated by the protein (Tao et al., 2002). While the BTV VP1 in vitro replicase activity was low, the activity was detectable for at least 24 hours at 37°C. VP1 was able to copy each of the plus-strand RNA segments fully, from the smallest BTV RNA (822 nt) to the largest BTV plus-strand RNA of 3954 nt. Each product was a complete duplex and was RNase I resistant, but RNase III sensitive, dsRNA. Further the minus-strand product was formed by de novo initiation rather than extension of a terminal hairpin-like structure in the template RNA. Surprisingly, given the well-documented template-specific binding of the polymerase of rotavirus (Patton, 1996; Patton et al., 1997; Patton & Chen, 1999; Tortorici et al., 2003), BTV VP1 replicated template RNAs that did not contain the conserved terminal hexanucleotide common to all BTV genome segments. This was also true of templates with termini that bore no resemblance at all to these conserved sequences, although the polymerase did have a preference for templates with a terminal C nucleotide. Interestingly, the reovirus λ3 polymerase, which has been shown to be a poly(C)-dependent poly(G) polymerase (Starnes & Joklik, 1993), is also capable of initiating dsRNA synthesis on a non-viral template in the absence of other viral and cellular proteins (Tao et al., 2002). Thus, BTV and reovirus polymerases show some common characteristics that are quite distinct from rotavirus which has a polymerase that is only active in the presence of the core protein VP2 (Patton et al., 1997; Tortorici et al., 2003). The BTV replicase activity appears to be much more similar to that reported for the dsRNA bacteriophage 6 polymerase protein P2 with respect to non-specificity. However, P2 does have a preference for templates with the authentic phage-RNA-like dinucleotide at the 3′ end of the template RNA but it will catalyse dsRNA synthesis on any template ssRNA (Makeyev & Bamford, 2000b, 2000a;Makeyev & Bamford, 2001).The replicase activity of VP1 alone is low, with only a small minority of the potential template molecules being replicated. It is probable that other viral proteins might act normally to modulate the efficient activity of VP1 in the assembling core particle and likely also provide template specificity. Indeed, the evidence from other viral replicase systems would seem to suggest that polymerase activities (e.g., hepatitis C polymerase) are highly regulated in vivo (Piccininni et al., 2002; Shirota et al., 2002). The confirmation of VP1 as the BTV polymerase protein was further provided by generating a structural model and by reconstitution studies. Since all DNA and RNA polymerases share a similar structure, and as RdRps are more similar to each other than to other polymerases, it was possible to postulate a VP1 3D structure based on several available RdRp crystal structures (Wehrfritz et al., 2007). All RdRp proteins adopt the typical polymerase structure of a right hand, complete with fingers, palm and thumb sub-domains. Co-crystallization of these enzymes with nucleoside triphosphates (NTP, or with oligonucleotides, has mapped substrate binding sites, while the binding of divalent cations, Mg2+ or Mn2+), has been mapped to the catalytic sites, normally characterized by a Gly-Asp-Asp (GDD) motif (Ng et al., 2002; Tao et al., 2002; Choi et al., 2004; Ferrer-Orta et al., 2004). The active site of these polymerases is at the centre of the molecule, in the centre of the palm domain. An additional domain, N-terminal to the fingers, that anchors the tips of the fingers to the thumb is also present in these RdRps (Tao et al., 2002; Choi et al., 2004). Beyond several conserved motifs, there is little primary sequence conservation among the RdRps of the RNA viruses in general, or among those of the dsRNA viruses. Reovirus λ3, which has a total of 1267 amino acids, is a similar size to BTV VP1 (1302 aa residues). The polymerase domain (PD) of λ3 is located in the centre of the molecule (Tao et al., 2002). In addition to PD, unlike the other RdRp, λ3 also possesses a large N- terminal domain (NTD) as well as a C-terminal domain (CTD) (Tao et al., 2002). The NTD of λ3 covers one side of the active site, and anchors the fingertips to the thumb. The CTD of λ3 which covers the catalytic cleft on the other side forms a bracelet structure with two tightly sealed circles. The opening in the centre of the bracelet forms the exit route for the nascent dsRNA (Tao et al., 2002). BTV VP1 has a GDD motif at position 763–765 which is surrounded by the other sequence motifs characteristic of polymerase proteins (Roy et al., 1988; Bruenn, 1991; 2003), which suggests that VP1 may have a single, central polymerase domain, similar to reovirus λ3. When submitted to a web-based server, 500 amino acid residues (aa581-880) in the central region of VP1 that include the GDD sequence produced alignments with the RdRps of two positive-sense ssRNA viruses, rabbit haemorrhagic disease virus (RHDV) and poliovirus (PV) (Wehrfritz et al., 2007). To generate a spatially restrained three-dimensional model of the polymerase domain of VP1, the final polymerase sequence alignments were then submitted together to a MODELLER program (Sali et al., 1995). The model shows a typical polymerase structure of VP1 with the canonical structure of a right hand with ‘fingers’, ‘palm’, and ‘thumb’ (Fig. 5
The ‘palm’ subdomain predicted for VP1 is composed of a four-stranded antiparallel β sheet flanked by three α helices. This is anarrangement universally found in polymerases. The architecture of the ‘palm’ region is the most highly conserved structure of all known polymerases and many of its features are shared across all families of RNA and DNA polymerases including the VP1 model (O’Reilly & Kao, 1998). The aspartate residues in motif C, which are predicted to be responsible for divalent cation co-ordination, are at positions 764 and 765 of VP1. Two additional aspartate residues believed to be involved in either metal ion coordination or the binding of NTPs are positioned in Motif A at residues 669 and 674 in the VP1 model (Appleby et al., 2005; Wehrfritz et al., 2007) The ‘thumb’ subdomain of modelled VP1 has three α-helices linked by loops. The ‘thumb’ subdomain of RdRps generally have four or more α helices that are preceded by a short β strand that is located between the ‘palm’ and the ‘thumb’ subdomains (Ng et al., 2002; Tao et al., 2002). In VP1, there is a gap in the polymerase domain alignment which indicates that this β-strand is missing in VP1. The ‘thumb’ of reovirus λ3 polymerase also has only three helices. Reovirus λ3 is the only RdRp from the Reoviridae for which the structure has been solved. The initial search of the SAM T-02 server database, using the central portion of BTV VP1 did not identify the equivalent regions of reovirus λ3 or bacteriophage 6 P2, the structures of which are known (Butcher et al., 2001; Tao et al., 2002). However, a subsequent search of the FUGUE server database (Shi et al., 2001) using the full-length VP1 recovered an alignment spanning the entire length of the VP1 protein with the sequence of reovirus λ3, suggesting that the polymerase domain of VP1 could also be modelled on λ3. The modelled regions that were obtained from this alignment showed a polymerase-type structure similar to the model already obtained and similar to the polymerase domain of λ3. A comparison of the root mean square deviation (RMSD) value between the complete polymerase domain model derived from PV and RHDV and the polymerase domain of reovirus λ3 indicated a 2.0 Å deviation (Wehrfritz et al., 2007).The λ3 structure was also used to model the amino-terminal and carboxy-terminal regions of BTV VP1. The models of both regions exhibited a high degree of structural similarity with these two regions of the λ3 structure (Fig. 5 The modelled CTD of VP1 has a bracelet structure like that of λ3. In λ3, this bracelet structure forms a pore through which the newly formed genomic dsRNA exits the polymerase. This VP1 domain has putative 20 α helices and 6 β strands, similar to the C-terminal region of λ3, indicating a very close structural similarity in this region of the molecule, and that the CTD of BTV VP1 also must form an exit pore for the nascent dsRNA (Fig. 5 To obtain biological evidence that the GDD motif located within the centre of the palm domain is essential for catalytic activity of VP1, this motif was mutated (DD764–765AA) in a recombinant VP1 protein. When tested in vitro, the recombinant mutant protein showed complete loss of catalytic activity, emphasising that the PD model is likely to be correct (Wehrfritz et al., 2007). Further, to verify the model structure biologically, three constructs were designed to express each of the three domains, PD, NTD and CTD, separately in an E. coli expression system. Each expressed fragment was then purified in soluble form and tested for its role in NTP-binding and polymerase activity. Neither the NTD nor the CTD showed any NTP-binding or RdRp activity. Only the PD alone showed efficient NTP binding activity although, it had no RdRp activity. Similarly, when the PD fragment was mixed either with NTD or with CTD, again no RdRp activity was achieved. In contrast, when soluble PD fragment was mixed together with the purified NTD and CTD fragments in vitro, the RdRp activity was reconstituted (Fig. 5 The second largest minor protein VP4 is the mRNA capping enzyme A fundamental feature of eukaryotic mRNAs is that they are modified co-transcriptionally by addition of a ‘cap’ at their 5′ end. The ‘cap’ is essentially a methyl-guanosine connected via a 5′-5′triphosphate linkage to the first nucleoside of the transcript (Furuichi et al., 1975; Shatkin & Both, 1976). The ‘cap’ structure stabilizes the newly synthesised mRNAs and allows efficient translation initiation of mRNAs (Rottman et al., 1974; Furuichi et al., 1975; Urushibara et al., 1975; Wei et al., 1975; Shatkin & Both, 1976; Parker & Song, 2004). Many eukaryotic viruses including members of the Reoviridae also ‘cap’ the 5′ termini of the RNA transcripts they synthesise. While many viruses use the cellular capping machinery, BTV and reoviruses encode their own capping enzymes. Since the newly synthesised transcripts of these viruses are readily capped prior to their release from the cores, the catalytic activities required for ‘cap’ formation must be provided by one or more proteins within the core. Current models for the transcription of the dsRNA genome of members of the Reoviridae are based on the polymerase complex contacting the template RNA and the nascent transcript being directed out of the core particle through a pore on its surface. In the case of reovirus, this pore is associated with a turret-like structure on the surface of the core that is formed from pentamers of a structural protein which possesses capping activity (Zhang et al., 2003). For rotavirus and BTV, where there are no turret structures present, the capping activity is associated with minor structural components that are located within the inner capsids (Le Blois et al., 1992). Formation of the cap structure requires at least three key enzymatic activities: (1) an RNA triphosphatase (RTase) that hydrolyses the 5′-triphosphate terminus of the mRNA to a diphosphate; (2) a guanylyltransferase (GTase) that caps the diphosphate terminus with GMP via a 5′-5′ triphosphate linkage, and (3) a guanine-N7-Methyltransferase (N7MTase) that adds a methyl group to the N7 position of the blocking guanosine. For BTV and reovirus transcripts, an additional nucleoside-2′-O-methyltransferase (2′OMTase) is also required. This enzyme is responsible to methylate the 2′-hydroxyl group of the ribose of the first nucleotide (namely type 1 cap). For BTV, based on the predicted amino acid sequence, the second largest minor protein VP4 (76.4 kDa), was predicted to possess some of these catalytic activities. Through the use of highly purified VP4 and recombinant CLPs containing VP4, it was shown that VP4 possesses an RNA 5′triphosphatase activity and can covalently bind GMP via a phosphoamide linkage as well as catalyse a GTP-PPi exchange reaction, both characteristic features of guanylyltransferase enzymes (Martinez Costas et al., 1998; Ramadevi et al., 1998b). Further direct evidence of VP4 capping activity was obtained by demonstrating in vitro transfer of GMP to the 5′ end of in vitro synthesized BTV ssRNA transcripts to form a cap structure. Moreover, VP4 was able to catalyze the conversion of unmethylated GpppG or in vitro-produced uncapped BTV RNA transcripts to a full cap structure, m7GpppGm, in the presence of S-adenosyl-L-methionine. Analysis of the methylated products of the reaction by HPLC identified both methyltransferase type 1 and type 2 activities associated with VP4, demonstrating that the complete BTV capping reaction is associated with this one protein (Ramadevi et al., 1998b). Thus, VP4 alone is responsible for the complete ‘cap’ structure at the 5′ ends of BTV transcripts. Cellular methyltransferase proteins typically appear to encode only a single activity (Reddy et al., 1992), whereas a number of viral methyltransferases, such as that encoded by vaccinia virus, have an additional enzymatic activity such as GTase (Martin et al., 1975; Martin & Moss, 1976). The nsP1 proteins of Semliki Forest virus and Sindbis virus (both positive-strand RNA viruses) also encode both methyltransferase and GTase activities (Mi et al., 1989; Laakkonen et al., 1994). In vaccinia virus, RTase, GTase and N7MTase are components of a capping enzyme complex containing two subunits of 95 kDa and 31 kDa (Venkatesan et al., 1980). However, 2′OMTase activity is mediated by an additional protein VP39 (Barbosa et al., 2002). In contrast to these viruses, BTV VP4 maximizes its coding capacity by catalyzing all of the capping and methylation steps necessary to form the complete type 1 cap structure. The protein also possesses an additional catalytic activity, an inorganic pyrophosphastase activity, which may aid the transcription activity within the virus by removing inorganic pyrophosphate which is an inhibitor of the polymerase reaction (Martinez Costas et al., 1998). BTV VP4 is thus the only capping enzyme in the family for which RTase, GTase and both MTase activities have all been formally demonstrated. This enzyme is unique in combining four capping enzyme activities into a single protein. Recently, the atomic structure of the protein has revealed how a single protein orchestrates all of these activities (Sutton et al., 2007). To date, almost all structural studies of enzymes associated with cap formation have involved proteins with only one of the activities needed for cap formation. The possible exception to this is reovirus for which a crystal structure of the core is available. In the 3.6 Å resolution structure of the orthoreovirus core, two methyltransferase domains were identified in the λ2 protein (Reinisch et al., 2000; Bujnicki & Rychlewski, 2001). However, as discussed above, the pentameric turret structures that form the orthoreovirus capping complex are missing in the BTV core. The 2.5 Å resolution crystal structure of recombinant BTV VP4 has revealed how VP4 achieves a series of catalytic activities in the absence of any other core proteins (Sutton et al., 2007). Surprisingly, there is no structural evidence that the capping machinery of BTV and orthoreovirus share a single common ancestor, which may have implications for the evolution of the family Reoviridae. The atomic structure reveals an elongated molecule with four discrete domains that are arranged in linear fashion (Fig. 6
There are extensive interactions between some domains in VP4 and a crystallographic 2-fold axis forms a potential dimmer, interface surface of which is contributed by amino acids within the N-terminal 114 and C-terminal 230 residues, in agreement with prior biochemical evidence (Ramadevi et al., 1998a). The GTase and N7MTase domains are closely associated, while the KL domain is reasonably strongly associated with both of these domains. In contrast, the 2′OMT domain is more isolated and only flexibly attached to the remainder of the molecule. But it is structurally similar to the catalytic domains of class I AdoMet-dependent methyltransferases. Superimpositions of the VP4 2′OMT domain on other capping structures show most similarity with the vaccinia virus VP39 structure (Fig. 7
RNA GTases are also varied in structure. The RNA GTases of Chlorella virus (Hakansson et al., 1997) and Candida albicans (Fabrega et al., 2004) show similarity to DNA and RNA ligases and consist of an N-terminal nucleotidyl transferase domain. The structure of the GTase domain of orthoreovirus (Reinisch et al., 2000) is quite different, suggesting that there is more than one family of such enzymes, utilising different structural motifs to execute a common reaction pathway. None of these structures could be identified in the GT domain of VP4 and no similar structures could be detected in the protein data bank. This domain is most likely responsible for the remaining two activities of VP4, RNA-triphosphatase (RTPase) and/or guanylyltransferase (GTase) activity. Indeed, by radiolabeled GTP binding assay followed by analysis of trypsin digested peptides, it has been shown that these two catalytic activities are associated with this domain (Sutton et al., 2007). The overall layout of active sites in a largely linear fashion along the molecule and the nature of the molecular surface between active sites are consistent with substrate channelling. The efficiency of the process must be optimised by a tight protein-protein interaction with the polymerase enzyme such that the emerging chain is capped almost immediately. Attachment of the KL domain to the polymerase would facilitate this since it is closest to the GT domain that is likely to perform the first two capping reactions on the emerging transcript. However, this possibility will only be confirmed by co-crystallizing the VP1-VP4 complex which is currently under investigation. Thus the combinations of molecular and structural studies have revealed how a single protein can achieve all the catalytic activities required to form the cap 1 structure at the 5′terminus of a de novo BTV RNA transcript. In summary, each of the three minor proteins of BTV core has the ability to function on its own and together they constitute a molecular motor that can unwind RNAs, synthesise ssRNAs of both polarities and modify the 5′ termini of the newly synthesised mRNA molecules. Much less is known about the in vivo RNA replication mechanisms of BTV. It is believed that, like other members of the family, the packaged plus-strand RNA serves as a template for synthesis of a minus-strand, and, once the minus-strand is synthesized, the dsRNA remains within the nascent progeny particle. As discussed, VP1 acts as the replicase enzyme but the roles of other proteins in minus-strand synthesis remain undefined. Due to the unique characteristics of BTV VP4 (combining all four capping activities in a single protein), the availability of the atomic structure of this protein represents an important opportunity to completely understand the molecular basis of an mRNA capping mechanism. BTV transcripts alone in the absence of any proteins can generate infectious virus The three proteins within the core particles of BTV are responsible for the synthesis and release of capped ssRNA transcripts into the cytoplasm of infected cells, using the genomic dsRNA segments as templates. However, apart from the production of viral ssRNA transcripts, the core particle itself has no other known role in infection. The extruded transcripts act as both mRNAs for the synthesis of the viral proteins and as templates for the synthesis of new dsRNA genome segments. In theory, both these roles would be satisfied if the viral ssRNA was delivered to the host cell cytoplasm by a route other than transcription from an infectious viral core. This notion has prompted an investigation of the possibility that BTV ssRNA could be infectious without the use of any helper virus. Initially viral ssRNA was synthesised in vitro from BTV cores that were purified from virions by chymotripsin treatment and after the transcription reactions, the active cores were then completely removed from the viral ssRNA transcripts. Transfection of these in vitro synthesized ssRNA transcripts into mammalian cells not only initiated all the viral protein synthesis but also led to the recovery of infectious virus (Boyce & Roy, 2007). The ability to recover infectious BTV wholly from ssRNA also suggested a means for establishing a helper virus-independent reverse genetics system for BTV. This was assessed by further extending the manipulation of BTV genes by the addition of one or more plasmid-derived T7 transcripts. Initially, as a proof of concept, it was demonstrated that cells transfected with a mixture of viral mRNAs from two serotypes of BTV could generate reassortant progeny genomes that contain genome segments derived from both parental sets of mRNA (Fig. 8
Alternative reverse genetics strategies have been used successfully for other genera in the Reoviridae (Roner & Joklik, 2001; Komoto et al., 2006; Kobayashi et al., 2007). The first reverse genetics system was a helper virus system for the mammalian orthoreoviruses (Roner & Joklik, 2001). This approach combined reovirus infection of permissive cells and transfection with viral dsRNA, viral mRNA, a T7 transcript, and in vitro translated viral mRNA. Another helper virus approach has allowed the replacement of a rotavirus outer capsid protein with the corresponding protein from another serotype (Komoto et al., 2006). The expression of the introduced genome segment was driven in vivo by the recombinant T7 vaccinia virus system, and selective pressure against the equivalent helper virus protein was provided by the use of antibody selection. Most recently, mammalian orthoreovirus has been recovered using a plasmid-based system similar to the T7 driven systems first used with negative strand viruses (Kobayashi et al., 2007) and, in this case, expression of all ten genome segments was driven in vivo by a recombinant T7 vaccinia virus system. Successful reverse genetics strategies to date all have several notable features in common: 1) the genome segments derived from cDNA clones are provided as message-sense transcripts in the transfected cell, 2) the cDNA-derived transcripts have the same 5′ end and 3′ end sequences as the corresponding viral transcript (5′ ends are generated through the use of a T7 promoter with the appropriate sequence, and 3′ ends are generated through the use of the hepatitis delta ribozyme in vivo or a restriction enzyme site in vitro), and 3) like authentic viral transcripts, the cDNA-derived transcripts are capped, either in vitro with a cap analogue or in vivo through the cross-capping activity associated with the vaccinia T7 RNA polymerase recombinant (Fuerst et al., 1989). As has been amply demonstrated for other viruses, a reverse genetics system for BTV should contribute to the further understanding of the virus in several research areas. The molecular dissection of BTV protein function to date has mainly been based on recombinant proteins. The ability to introduce specific mutations into the genes of BTV will further our understanding of the functions of these viral proteins in replicating virus and allow the corroboration of the enzymatic or structural functions already assigned. The cis-acting RNA sequences that control the replication, packaging, and expression of orbivirus genomes remain unmapped, and are poorly understood. Reverse genetics will allow the mapping of these regulatory sequences and an investigation of their functions. The replacement of outer capsid proteins can be used to generate vaccine strains with different serotypes based on a common genetic background and it may be possible to identify the determinants of pathogenicity of BTV and related orbiviruses such that strains with varying levels of attenuation could be generated. Future perspectives As a result of extensive molecular and structural studies BTV represents an important model system for the study of other viruses. In the infected cells the core of the virus particle is transcritionally active. Its activity marks the beginning of the virus infection cycle and an understanding of its function is therefore fundamental to the biology of virus infection. The structure of the core of dsRNA viruses within the family Reoviridae has revealed a functional molecular machine dedicated to the efficient transcription of RNA upon cell entry, so initiating the infectious cycle. Significant progress has been made in understanding the function of each of the proteins of the BTV core. The present level of understanding has required a merging of structural and molecular studies to map the protein-protein interactions within the core with biochemistry of individual reactions within the protein microenvironment, and represents a novel and holistic approach to uncovering the action of the virion core. It is still the case, however, that the described activity of each individual core protein is incomplete and that a complete understanding of how the core proteins act in concert is lacking. It is becoming increasingly clear that further understanding of the molecular mechanism of these enzymes requires a more thorough understanding of their structure and functional relationship as a complex. Several significant questions still remain, however, regarding the mechanism of the enzymatic reactions that are catalysed by each protein, the assembly of the proteins in the transcriptase complex, how substrates pass from one component to the next, and, in the case of the helicase protein VP6, the precise role of the protein in the transcription process. Current understanding is that the polymerase complex contacts the template RNA and the dsRNA is used to produce transcripts. How does the polymerase make a copy-choice between the plus- and minus-strand RNAs? The only physical feature that differs between these strands as they are found in the viral genomic RNA is that only the plus-strand RNA has a cap structure. Does VP1 also possesses a cap-binding domain, and is it the recognition of the cap structure juxtaposed with the 3′ end of the viral minus-strand that positions the start of the minus-strand for transcription activity? The purified VP1, VP4 and VP6 have RdRp, capping and helicase activities respectively in vitro, but what is the precise order of contacts between proteins that allow formation of this complex and how does this relate to efficient enzyme function and processivity as a whole? In addition, the ability to introduce specific mutations into BTV genes, particularly in the polymerase or helicase genes in replicating virus, will allow the corroboration of the enzymatic or structural functions already assigned. Such studies will also reveal if mutations in polymerase or helicase proteins have any significance in virus replication and pathogenesis in the variety of hosts that BTV infects as appears to be the case for influenza virus (Finkelstein et al., 2007). Acknowledgments This work was partly supported by the Biotechnology and Biological Sciences Research Council, UK and partly by National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA. References
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||||||
Prog Clin Biol Res. 1985; 178():7-12.
[Prog Clin Biol Res. 1985]Prog Clin Biol Res. 1985; 178():7-12.
[Prog Clin Biol Res. 1985]Subcell Biochem. 1989; 15():233-73.
[Subcell Biochem. 1989]J Virol. 2007 May; 81(9):4819-27.
[J Virol. 2007]J Struct Biol. 1992 Jul-Aug; 109(1):61-9.
[J Struct Biol. 1992]J Struct Biol. 1994 May-Jun; 112(3):183-91.
[J Struct Biol. 1994]J Virol. 2004 Aug; 78(15):8059-67.
[J Virol. 2004]Subcell Biochem. 1989; 15():233-73.
[Subcell Biochem. 1989]J Virol. 2007 May; 81(9):4819-27.
[J Virol. 2007]J Virol. 2007 May; 81(9):4819-27.
[J Virol. 2007]Proc Natl Acad Sci U S A. 2004 Feb 17; 101(7):2100-5.
[Proc Natl Acad Sci U S A. 2004]Onderstepoort J Vet Res. 1982 Dec; 49(4):227-32.
[Onderstepoort J Vet Res. 1982]Virology. 1987 Mar; 157(1):180-8.
[Virology. 1987]Virology. 1987 Apr; 157(2):375-86.
[Virology. 1987]J Virol. 1970 Jan; 5(1):1-7.
[J Virol. 1970]J Virol. 1972 Oct; 10(4):783-94.
[J Virol. 1972]J Gen Virol. 1989 Jul; 70 ( Pt 7)():1677-89.
[J Gen Virol. 1989]Curr Top Microbiol Immunol. 1990; 162():43-87.
[Curr Top Microbiol Immunol. 1990]Onderstepoort J Vet Res. 1982 Dec; 49(4):227-32.
[Onderstepoort J Vet Res. 1982]Onderstepoort J Vet Res. 1968 Jun; 35(1):139-49.
[Onderstepoort J Vet Res. 1968]Curr Top Microbiol Immunol. 1990; 162():89-118.
[Curr Top Microbiol Immunol. 1990]J Gen Virol. 1990 Sep; 71 ( Pt 9)():2073-83.
[J Gen Virol. 1990]J Virol. 2003 Nov; 77(21):11347-56.
[J Virol. 2003]J Biol Chem. 2003 Aug 22; 278(34):31722-30.
[J Biol Chem. 2003]Virology. 1980 Jul 30; 104(2):347-56.
[Virology. 1980]J Gen Virol. 1988 Mar; 69 ( Pt 3)():573-81.
[J Gen Virol. 1988]J Virol. 1992 Apr; 66(4):2135-42.
[J Virol. 1992]Structure. 1997 Jul 15; 5(7):885-93.
[Structure. 1997]Nature. 1998 Oct 1; 395(6701):470-8.
[Nature. 1998]Nature. 1998 Oct 1; 395(6701):470-8.
[Nature. 1998]Cell. 1999 May 14; 97(4):481-90.
[Cell. 1999]J Gen Virol. 1989 Jul; 70 ( Pt 7)():1677-89.
[J Gen Virol. 1989]J Virol. 1970 Jul; 6(1):1-11.
[J Virol. 1970]Proc Natl Acad Sci U S A. 1970 Sep; 67(1):275-81.
[Proc Natl Acad Sci U S A. 1970]J Gen Virol. 1989 Jul; 70 ( Pt 7)():1677-89.
[J Gen Virol. 1989]J Gen Virol. 1992 Dec; 73 ( Pt 12)():3051-64.
[J Gen Virol. 1992]Cell. 1998 Apr 3; 93(1):9-12.
[Cell. 1998]Mol Microbiol. 1992 Feb; 6(3):283-91.
[Mol Microbiol. 1992]J Virol. 1997 Apr; 71(4):2583-90.
[J Virol. 1997]Trends Biochem Sci. 1999 May; 24(5):192-8.
[Trends Biochem Sci. 1999]Mol Cell. 2001 Oct; 8(4):734-6.
[Mol Cell. 2001]J Biol Chem. 1997 Dec 19; 272(51):32267-73.
[J Biol Chem. 1997]Nucleic Acids Res. 1998 Jun 1; 26(11):2686-93.
[Nucleic Acids Res. 1998]Cell. 1998 Apr 3; 93(1):9-12.
[Cell. 1998]Virology. 2004 Jul 1; 324(2):387-99.
[Virology. 2004]J Mol Biol. 1991 Oct 20; 221(4):1127-38.
[J Mol Biol. 1991]J Gen Virol. 1989 Jul; 70 ( Pt 7)():1677-89.
[J Gen Virol. 1989]J Gen Virol. 1989 Jun; 70 ( Pt 6)():1453-63.
[J Gen Virol. 1989]J Virol. 2004 Apr; 78(8):3994-4002.
[J Virol. 2004]Virology. 1980 Jul 30; 104(2):347-56.
[Virology. 1980]Virology. 1984 May; 135(1):207-17.
[Virology. 1984]J Biol Chem. 2002 Nov 22; 277(47):45670-9.
[J Biol Chem. 2002]J Biol Chem. 2002 Mar 29; 277(13):11149-55.
[J Biol Chem. 2002]Biopolymers. 2007 May; 86(1):83-94.
[Biopolymers. 2007]J Biol Chem. 2002 Jan 11; 277(2):1381-7.
[J Biol Chem. 2002]Cell. 2002 Nov 27; 111(5):733-45.
[Cell. 2002]Proc Natl Acad Sci U S A. 2004 Mar 30; 101(13):4425-30.
[Proc Natl Acad Sci U S A. 2004]J Biol Chem. 2004 Nov 5; 279(45):47212-21.
[J Biol Chem. 2004]Nucleic Acids Res. 1988 Dec 23; 16(24):11759-67.
[Nucleic Acids Res. 1988]Nucleic Acids Res. 1991 Jan 25; 19(2):217-26.
[Nucleic Acids Res. 1991]Nucleic Acids Res. 2003 Apr 1; 31(7):1821-9.
[Nucleic Acids Res. 2003]Biopolymers. 2007 May; 86(1):83-94.
[Biopolymers. 2007]Proteins. 1995 Nov; 23(3):318-26.
[Proteins. 1995]Virology. 1998 Dec 20; 252(2):287-303.
[Virology. 1998]J Virol. 2005 Jan; 79(1):277-88.
[J Virol. 2005]Biopolymers. 2007 May; 86(1):83-94.
[Biopolymers. 2007]J Biol Chem. 2002 Jan 11; 277(2):1381-7.
[J Biol Chem. 2002]Cell. 2002 Nov 27; 111(5):733-45.
[Cell. 2002]Nature. 2001 Mar 8; 410(6825):235-40.
[Nature. 2001]Cell. 2002 Nov 27; 111(5):733-45.
[Cell. 2002]J Mol Biol. 2001 Jun 29; 310(1):243-57.
[J Mol Biol. 2001]Biopolymers. 2007 May; 86(1):83-94.
[Biopolymers. 2007]Cell. 2002 Nov 27; 111(5):733-45.
[Cell. 2002]Biopolymers. 2007 May; 86(1):83-94.
[Biopolymers. 2007]Proc Natl Acad Sci U S A. 1975 Feb; 72(2):742-5.
[Proc Natl Acad Sci U S A. 1975]Cell. 1976 Mar; 7(3):305-13.
[Cell. 1976]Cell. 1974 Nov; 3(3):197-9.
[Cell. 1974]FEBS Lett. 1975 Jan 1; 49(3):385-9.
[FEBS Lett. 1975]Cell. 1975 Apr; 4(4):379-86.
[Cell. 1975]J Mol Biol. 1998 Jul 31; 280(5):859-66.
[J Mol Biol. 1998]Proc Natl Acad Sci U S A. 1998 Nov 10; 95(23):13537-42.
[Proc Natl Acad Sci U S A. 1998]Pharmacol Ther. 1992; 54(3):249-67.
[Pharmacol Ther. 1992]J Biol Chem. 1975 Dec 25; 250(24):9322-9.
[J Biol Chem. 1975]J Biol Chem. 1976 Dec 10; 251(23):7313-21.
[J Biol Chem. 1976]Nat Struct Mol Biol. 2007 May; 14(5):449-51.
[Nat Struct Mol Biol. 2007]Nature. 2000 Apr 27; 404(6781):960-7.
[Nature. 2000]Genome Biol. 2001; 2(9):RESEARCH0038.
[Genome Biol. 2001]Nat Struct Mol Biol. 2007 May; 14(5):449-51.
[Nat Struct Mol Biol. 2007]J Virol. 1998 Apr; 72(4):2983-90.
[J Virol. 1998]Genome Biol. 2001; 2(9):RESEARCH0038.
[Genome Biol. 2001]EMBO J. 2002 Jun 3; 21(11):2757-68.
[EMBO J. 2002]Mol Cell. 1998 Feb; 1(3):443-7.
[Mol Cell. 1998]Biochemistry. 2004 May 18; 43(19):5680-7.
[Biochemistry. 2004]Cell. 1997 May 16; 89(4):545-53.
[Cell. 1997]Mol Cell. 2004 Jan 16; 13(1):77-89.
[Mol Cell. 2004]Nature. 2000 Apr 27; 404(6781):960-7.
[Nature. 2000]Nat Struct Mol Biol. 2007 May; 14(5):449-51.
[Nat Struct Mol Biol. 2007]J Virol. 2007 Mar; 81(5):2179-86.
[J Virol. 2007]Proc Natl Acad Sci U S A. 2001 Jul 3; 98(14):8036-41.
[Proc Natl Acad Sci U S A. 2001]Proc Natl Acad Sci U S A. 2006 Mar 21; 103(12):4646-51.
[Proc Natl Acad Sci U S A. 2006]Cell Host Microbe. 2007 Apr 19; 1(2):147-57.
[Cell Host Microbe. 2007]Proc Natl Acad Sci U S A. 1989 Apr; 86(8):2549-53.
[Proc Natl Acad Sci U S A. 1989]J Virol. 2007 Oct; 81(19):10292-9.
[J Virol. 2007]J Virol. 1992 Apr; 66(4):2135-42.
[J Virol. 1992]Structure. 1997 Jul 15; 5(7):885-93.
[Structure. 1997]J Virol. 2004 Aug; 78(15):8059-67.
[J Virol. 2004]J Virol. 1997 Oct; 71(10):7220-6.
[J Virol. 1997]J Virol. 2003 Nov; 77(21):11347-56.
[J Virol. 2003]Cell. 2002 Nov 27; 111(5):733-45.
[Cell. 2002]Biopolymers. 2007 May; 86(1):83-94.
[Biopolymers. 2007]Nat Struct Mol Biol. 2007 May; 14(5):449-51.
[Nat Struct Mol Biol. 2007]Nat Struct Mol Biol. 2007 May; 14(5):449-51.
[Nat Struct Mol Biol. 2007]J Virol. 2007 Mar; 81(5):2179-86.
[J Virol. 2007]